Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The initiative is focused on a problem that continues to plague cancer outcomes in India
Subscribe To Our Newsletter & Stay Updated
